# Luspatercept vs Epoetin in Treating Poor Erythroid Engraftment for Hematological Malignancies

> **NCT07636486** · PHASE2,PHASE3 · NOT_YET_RECRUITING · sponsor: **Nanfang Hospital, Southern Medical University** · enrollment: 90 (estimated)

## Conditions studied

- Luspatercept
- Epoetin
- Poor Erythroid Engraftment
- Hematological Malignancies

## Interventions

- **DRUG:** Luspatercept
- **DRUG:** Epoetin

## Key facts

- **NCT ID:** NCT07636486
- **Lead sponsor:** Nanfang Hospital, Southern Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-06-15
- **Primary completion:** 2028-06-30
- **Final completion:** 2030-12-31
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2026-06-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07636486

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07636486, "Luspatercept vs Epoetin in Treating Poor Erythroid Engraftment for Hematological Malignancies". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07636486. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*